Juno Therapeutics

Juno Therapeutics appoints Ann L. Lee Executive Vice President of Technical Operations

Monday, November 27, 2017

Juno Therapeutics, a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, announced the appointment of Ann L. Lee, Ph.D., as Executive Vice President of Technical Operations. Dr. Patrick Y. Yang will assume the role of Executive Vice President, Senior Advisor to the CEO. Both will report to Hans Bishop, President and CEO, and work to further advance Juno as a global leader in T cell engineering and manufacturing.

[Read More]

Executives of Juno Therapeutics under investigation

Monday, August 14, 2017

Shareholder and consumer rights law firm Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of Juno Therapeutics breached their fiduciary duties to Juno and its shareholders by exposing Juno to civil liability for failing to disclose patient deaths in the phase II/ROCKET trial of its leading product candidate, JCAR015, during the period June 24, 2016, to November 22, 2016. 

[Read More]

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]

Juno, WuXi launch JW Biotechnology in China

Monday, April 11, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and WuXi AppTec, an open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, have started a new company in China. JW Biotechnology (Shanghai) Co., Ltd‘s mission is to build China’s  cell therapy company by leveraging Juno’s world-class chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies together with WuXi AppTec’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solidorgan cancers. 

[Read More]